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Abstract: Androgen receptor (AR) signaling remains crucial in castration-resistant prostate cancer
(CRPC). Since it is also essential in immune cells, we studied whether the expression of AR full-length
(ARFL) and its splicing variant ARV7 in peripheral blood mononuclear cells (PBMC) predicts systemic
treatment response in mCRPC in comparison with circulating-tumor cells (CTC). We measured ARFL
and ARV7 mRNA in PBMC and CTC from patients prior to receiving abiraterone (AA), enzalutamide
(E), or taxanes by a pre-amplification plus quantitative reverse-transcription PCR. They were also
tested in LNCaP-ARV7-transfected and in 22RV1 docetaxel-resistant (22RV1DR) cells. We studied 171
PBMC from 136 patients and from 24 non-cancer controls, and 47 CTC from 22 patients. High PBMC
ARV7 levels correlated with worse AA/E and better taxane response. In taxane-treated patients
high PBMC ARFL also correlated with longer progression-free survival (PFS). High ARV7 and ARFL
expression were independently associated with better biochemical-PFS. Conversely, high CTC ARV7
and ARFL correlated with shorter radiological-PFS and overall survival, respectively. High ARV7 in
22RV1DR and LNCaP-ARV7 cells correlated with taxane resistance. In conclusion, ARFL and ARV7 at
PBMC or CTC have a different predictive role in the taxane response, suggesting a potential influence
of the AR pathway from PBMC in such response modulation.
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1. Introduction
Androgen receptor (AR) signaling activation plays an important role in the progression of
metastatic castration-resistant prostate cancer (CRPC). Targeting AR with the androgen synthesis
inhibitor abiraterone (AA) and the AR signaling inhibitor enzalutamide (E), has shown survival benefit
in such diseases [1–4]. Taxanes have also shown an inhibitory effect over AR signaling apart from their
anti-microtubule effect [5].
Constitutively active AR splicing variants have been identified as an important mechanism of the
AR pathway activation in conditions of androgen depletion [6]. The most studied form has been the
variant 7 (ARV7), which lacks the AR ligand-binding domain and is constitutively activated in absence
of androgens [6]. Detected in circulating tumor cells (CTC) [7] or in whole blood [8,9] ARV7 has been
associated with lower AA/E activity. However, controversial studies report its role as a biomarker of
taxane response [10–13].
Alternative splicing is a normal process in vertebrates and it is correlated with the complexity of
the organism [14,15]. AR splicing variants have been identified in healthy human tissues and it has been
speculated that the conservation of the AR splicing pattern in different tissues and in evolutionarily
distant vertebrate species could indicate the functional importance of these AR forms [14].
Because AR is expressed in blood cells, this tissue has been demonstrated to be feasible for
diagnosing genetic disorders affecting AR, such as androgen insensitivity syndrome [16]. Peripheral
blood mononuclear cells (PBMC) mainly consist of lymphocytes and monocytes, but may also contain
CTC. In prior work, we showed that the expression of deregulated prostate cancer genes can be
detected in PBMC from patients with mCRPC [17]. Specifically, the detection of specific prostate cancer
genes such as TMPRSS2-ERG could act as a potential biomarker of taxane resistance [18,19].
In this study we show the non-prostate cancer-specific detection of ARV7 mRNA in PBMC.
Moreover, our results suggest a different role of ARV7 mRNA in taxane response when detected in
PBMC vs. CTC samples in mCRPC patients.
2. Materials and Methods
2.1. Design and Sensitivity Measurement of ARV7 Detection
Primer Express software v3.0 was used to design a primer/probe set to detect ARV7. Specifically,
TaqMan probe was designed for the exon 3-cryptic exon 3 (CE3) boundary. The sequence of
the selected probe was 5′-tgggagaaaaattccgg-3′. For selected primers the forward sequences was
5’-gaaatgttatgaagcagggatgact-3’ and the reverse sequence was 5’-ggtcattttgagatgcttgcaa-3’. Using this
pair of primers, we expected an amplicon of 73 bp length. The sensitivity of the assay was tested by
diluting 22RV1 cells (which express ARV7) from 0 to 2000 cells in 1 × 106 PC-3 cells (which do not
express ARV7) (Figure 1). RNA extraction and quantitative reverse-transcription PCR (qRT-PCR) were
performed as described below. To confirm the ARV7 sequence, amplicons obtained by qRT-PCR from
22RV1 cell line (positive control), PBMC from three controls, and three CRPC patients were cloned and
sequenced. Specifically, the 73 bp PCR products were purified with PureLink Quick Gel Extraction Kit
(Invitrogen, Waltham, MA, USA) following manufacturer instructions. DNA fragments were ligated
into pJET1.2/blunt vector using the sticky-end protocol from CloneJET PCR Cloning Kit (Thermo
Scientific, Waltham, MA, USA). The constructs were transformed into Escherichia coli DH5α competent
cells by heat shock and plated on Luria-Bertani agar supplemented with carbenicillin (100 µg/mL).
Plasmids from single colony transformants were purified by Zyppy Plasmid Miniprep Kit (Zymo
Research, Irvine, CA, USA) according to manufacturer recommendations. The ARV7 amplicon was
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finally confirmed by sequencing the plasmids with pJET1.2 forward and reverse primers (Beckman
Coulter Genomics, Indianapolis, IN, USA).
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Helsinki, and the protocol was approved by the Ethics Committee of Hospital Clinic (Code 
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selection of CD4 and CD8 T-cells, B-lymphocytes, monocytes, and T-natural killer cells (NK) was 
performed using the automated MACS technology (Miltenyi Biotec, Bergisch Gladbach, Germany). 
Furthermore, CD4 T-cells from four blood donors were isolated by using the human TCD4+ cell 
isolation kit (Miltenyi Biotec), following manufacturer’s instructions. T-cells were stimulated with α-
CD3/CD28 beads (Life Technologies, Carlsbad, CA, USA) for three days. After 24 h of seeding cells, 
they were treated with 5 nM of 5α-dihydrotestosterone (DHT; Sigma-Aldrich, St. Louis, MO, USA) 
Figure 1. Scheme of patients included in this study. PBMC: peripheral blood mononuclear cells; AA/E:
airaterone/enzalutamide; CTC: circulating tumor cells; N: number of patients.
2.2. Patients, Controls, and Samples
Men with mCRPC, according to Prostate Cancer Working Group 2 (PCWG2) criteria [20], who
were candidates for AA, E, or taxa es we e eligible for the present study. Twenty-fou non-cancer
individuals (20 m n and four w men; mean age 45.2 y ars (range 23.8–72.4 ears) were included s
negative controls; nin were healthy volunteers and 15 were dmitted at the hospital for non-oncologic
surg ry (seven u inary lithiasis, t ree urinary incontinence, t o renal transplantation, two penile
prosthesis, and one urethral stenosis). Four of them were used for PBMC subpopulation analysis
(Figure 1). Patients were treated with E 160 mg/day orally, AA 1000 mg/day orally, or docetaxel
75 mg/m2 intravenous every 3 weeks, th last t o in association with prednisone 10 g/day ll
until unacc ptable toxicity or pr gression. Dis ase progression and treatment response were defined
acc rding to PCWG2 criteria [20,21]. PSA levels were measur d monthly. Computed tomogra hy and
bone scans were performed every two to four months or when clinically indicated. PSA-progression-free
survival (PSA-PFS), radiologic-PFS (RX-PFS), and overall survival (OS) were calculated from the
date of treatm nt i itiation to PSA progression, RX progression, and death or l st follow-up visit,
respectively. The study was conducted in accorda ce with the Declaration of Helsinki, and the protocol
was approved by the Ethi s Committee of Hospital Clini (Code HCB/2015/0342). All participants
provided written informed consent.
2.3. PBMC Subpopulation Isolation and TCD4+ Selection
Five peripheral blood samples (10 mL/each) from four non-oncologic controls were collected in
EDTA–containing vacutainers (Sarstedt, Nü brecht, Germany). Mag etic isolation through negative
selection of CD4 a d CD8 T-c lls, B-lymphocytes, monocytes, and T-natural killer cells (NK) was
performed using the utomated MACS technol g (Milte yi Biotec, Bergisch Gladbach, Germany).
Cells 2020, 9, 203 4 of 19
Furthermore, CD4 T-cells from four blood donors were isolated by using the human TCD4+ cell
isolation kit (Miltenyi Biotec), following manufacturer’s instructions. T-cells were stimulated with
α-CD3/CD28 beads (Life Technologies, Carlsbad, CA, USA) for three days. After 24 h of seeding cells,
they were treated with 5 nM of 5α-dihydrotestosterone (DHT; Sigma-Aldrich, St. Louis, MO, USA) and
60 uM of enzalutamide (Deltaclon, Madrid, Spain) in monotherapy and combined for 48 h by triplicate.
2.4. PBMC Isolation, RNA Extraction and qRT-PCR
Before treatment initiation, peripheral blood samples (10 mL) were collected in Monovette
EDTA–containing vacutainers (Sarstedt). A prior tube with 5 mL of blood was extracted and discarded
to avoid epithelial contamination during venipuncture. Samples were kept at 4 ◦C for up to 2 h until
processing. Blood specimens were layered onto 10 mL of Ficoll-Paque (GE Healthcare Life Sciences,
Issaquah, WA, USA). After centrifugation, PBMC were isolated, and total RNA was extracted using
TRI-Reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to manufacturer instructions.
RNA was quantified by ND-1000 spectrophotometer (Nanodrop Technologies, Thermo Fisher Scientific).
Then, 0.5 ug of total RNA was reverse transcribed using the High Capacity cDNA Archive Kit (Thermo
Fisher Scientific) following manufacturer instructions. Target genes were preamplified for 14 cycles,
following manufacturer instructions for the TaqMan PreAmp Master Mix Kit (Thermo Fisher Scientific),
except that the final volume of the reaction was reduced to 25 µL. QRT-PCR was performed in a
StepOnePlus Real-Time PCR system (Life Technologies) according to manufacturer recommendations.
Data were acquired using SDS Software 1.4. Amplification reactions were performed in duplicate.
Expression values were based on the quantification cycle (Cq) from target genes relative to the Cq of
GUSB endogenous gene. Commercial codes for primers and probes were used to amplify ARFL, KLK3,
PTPRC, and GUSB genes (Hs00907244_m1, Hs03063374_m1, Hs00236304_m1, and Hs99999908_m1,
respectively; Thermo Fisher Scientific). A specific combination of primers and TaqMan probe for
detecting ARV7 was used and described above.
2.5. CTC Enrichment
Blood CTC enrichment was performed using the IsoFlux System (Fluxion Biosciences, South San
Francisco, CA, USA). Two 10 mL EDTA tubes were collected from patients before taxane initiation
and after three cycles or at progression. One of the tubes was used for CTC counting with the IsoFlux
CTC Enumeration Kit, according to manufacturer’s instructions. CTC were defined as nucleated cells,
morphologically intact, cytokeratin positive, and CD45 negative cells. The second EDTA tube was
used for gene expression analysis. Briefly, PBMC were isolated by Ficoll (GE Healthcare, Uppsala,
Sweden) gradient and incubated with anti-epithelial cell adhesion molecule (EpCAM), prostate stem
cell antigen (PSCA), and N-cadherin (CDH2)-coated beads for 2 h at 4 ◦C. Cell–bead complexes were
loaded into Isoflux cartridges to be isolated automatically by the instrument. Cells returned by the
instrument were stained or total RNA was extracted and qRT-PCR with cDNA preamplification was
performed as described above, using ACTB (Hs99999903_m1) as endogenous gene.
2.6. In Vitro Experiments
LNCaP cells with doxycycline-inducible expression of ARV7 and their respective control
LNCaP-vector cells were kindly provided by Dr. Nancy L. Weigel [22]. 22RV1 resistant to docetaxel
(22RV1DR) and their respective control cells were kindly provided by Dr. Ajit Verma [23].
Whole-cell extracts of LNCaP induced with doxycycline were prepared and Western blot performed
as described previously [22] in order to confirm the inducible ARV7 expression. Mouse anti-ARV7
1:500 (Precision antibody) and GAPDH (Ref. AM4300, Ambion, Austin, TX, USA) antibodies were
used. The Odyssey fluorescence system was used to detect protein signals.
Cytotoxicity of taxanes, docetaxel, and cabazitaxel (Selleckchem, Munich, Germany),
was evaluated by using the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay kit (Promega,
Madison, WI, USA) according to manufacturer’s instructions. Briefly, 10 thousand cells/well were
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seeded at 96-well plates and induced with 10 ng/mL doxycycline. Twenty-four hours later cells
were treated with increasing concentrations of both docetaxel and cabazitaxel and cell viability was
evaluated after 72 h of treatment.
2.7. Statistical Analysis
Fisher’s exact and Wilcoxon–Mann–Whitney tests were used to compare proportions and
continuous variables, respectively. Optimal cut-off points for ARV7 and ARFL, and PSA-PFS, RX-PFS,
and OS were assessed by the maximally selected log-rank statistics method using the Maxstat package
in R software [24]. Briefly, to run this test the smethod and pmethod were log-rank and Lau92,
respectively, and the minimal and maximal proportions were 0.3 and 0.7, respectively, with an alpha
error of 0.05. ARV7 and ARFL expression levels were considered high or low according to the optimal
cut-off points selected. PSA-PFS, RX-PFS, and OS were calculated using the Kaplan-Meier method
and compared using the log-rank test. Univariate and multivariate analysis were performed with Cox
regression. QRT-PCR experimental data were analyzed by Student T-test. All tests were 2-sided and
P values < 0.05 were considered statistically significant. Statistical analysis was done with SPSS (v20)
and R-Studio software (v3.1.1) [25].
3. Results
3.1. ARV7 Amplification Efficiency, Sensitivity, and Sequence Confirmation
The 22RV1 cell line, which expresses ARV7, was used to assess the effectiveness of the designed
primers in amplification of ARV7 (Figure 1) by cDNA pre-amplification plus qRT-PCR. Efficiency was
evaluated by performing a standard curve with a 10-fold dilution series of 22RV1 cDNA. The slope of the
curve for ARV7 expression was −3.387, indicating an assay efficiency of 97.4%. GUSB slope and efficiency
were −3.41% and 96.4%, respectively (Figure 1). Spiking experiments showed the capacity to detect ARV7
expression if five 22RV1 cells were pooled among 1 × 106 PC-3 cells (Figure 1). ARV7 amplicon was
cloned into the pJET1.2/blunt vector in order to confirm its sequence in 22RV1 and in PBMC from controls
and CRPC patients. The obtained sequence was the expected according to the primers used, confirming
the ARV7 detection in non-prostate cancer individuals and in patients with mCRPC (Figure 2).
3.2. ARV7 and ARFL Expression in PBMC from Non-Cancer Patients
To explore the basal levels of ARV7 and ARFL in the non-cancer population we collected PBMC from
twenty-four non-cancer individuals. ARV7 was detected in 18 of them (75%) and ARFL in all the samples
(100%). To further confirm the expression of ARV7 and ARFL in PBMC we studied five subpopulations
(CD4 and CD8 T-cells, B lymphocytes, T-natural killer cells [NK], and monocytes) isolated from PBMC
of four non-cancer controls. ARV7 mRNA was detected in T-CD4 and B-lymphocytes from two (50%)
controls, in T-CD8 and NK cells from one (25%) individual, and in the monocyte subpopulation from
all four (100%) controls. ARFL was detected in all subpopulations from all controls except for the NK
population of one individual (Table 1).
Table 1. Detection of ARV7 and ARFL in PBMC subpopulations from four non-cancer controls.
Samples (ARV7/ARFL) 1
Cell Type S1 S2 S3 S4
T-CD4 lymphocytes +/+ −/+ +/+ −/+
T-CD8 lymphocytes +/+ −/+ −/+ −/+
B lymphocytes −/+ +/+ −/+ +/+
NK cells +/− −/+ −/+ −/+
monocytes +/+ +/+ +/+ +/+
1 mRNA detection is represented by +; if mRNA was not detected is showed as −; S: sample; NK: natural killer.
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expression in this work. * Translation stop. F: forward primer; P: probe; R: reverse primer; CE: cryptic 
exon. (B) Standard curve with 10-fold dilution series of 22RV1 cDNA graphs showing the efficiency 
of the designed ARV7 TaqMan assay in comparison with the GUSB assay. The efficiency ‘E’ factor 
was calculated according to the formula E = [10^(−1/slope)] − 1. Linear regression analysis showed the 
slope of the curves. Cq: quantification cycle. (C) Bar plot and linear regression analysis of ARV7 
detection in spiking experiments. The number of spiked cells and fold change detected are plotted on 
the y- and x-axis, respectively. The correlation coefficient is given at the top of the linear regression 
Figure 2. Design and sensitivity of ARV7 detection assay. (A) Androgen receptor (AR) full- length
(ARFL) ene and ARV7 transcripts scheme that show primers and prob design for detecting ARV7
expression in this work. * Translation stop. F: forward primer; P: probe; R: reverse primer; CE: cryptic
exon. (B) Standard curve with 10-fold dilution series of 22RV1 cDNA graphs showing the efficiency
of the designed ARV7 TaqMan assay in comparison with the GUSB assay. The efficiency ‘E’ factor
was calculated according to the formula E = [10ˆ(−1/slope)] − 1. Linear regression analysis showed
the slope of the curves. Cq: quantification cycle. (C) Bar plot and linear regression analysis of ARV7
detection in spiking experiments. The number of spiked cells and fold change detected are plotted on
the y- and x-axis, re p ctively. The correlatio fficient is given at the t p of th lin ar regression
graph. (D) Agarose gel of ARV7 quantitative PCR product in 22RV1 cell line (positive control) and in
PBMC from three controls (J, M, and E) and three mCRPC patients (12, 36, and 34). Negative control
(H2O ct.) was included. Sequence of one of the cloned control bands is showed. MW: 50 bp molecular
marker (Niborlab).
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To explore the potential effect of anti-androgen treatment on ARV7 and ARFL mRNA expression
in PBMC we exposed a subpopulation (CD4 T-cells) from non-cancer controls to DHT or E. With the
experimental conditions used, we showed that E significantly increased the expression of ARFL in one
(25%) of the four controls (2.21-fold relative to E vehicle; P < 0.05) while non-significant changes were
observed in ARV7 and ARFL expression with DHT or E treatment (Figure 3).
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(16.7%) no CTC were detected; the remaining 10 (83.3%) had a median CTC count of 8.5 (range 1–22). 
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all samples in both PBMC and CTC. Significantly higher levels of ARV7 and KLK3, but not ARFL, 
expression were found in CTC samples, compared to PBMC (Figure 4). Although non-significant, 
higher levels of the prostate-specific marker KLK3 were in CTC-positive samples (≥1 CTC vs. <1 CTC) 
and in samples with CTC equal to or more than five (Figure 4). 
Figure 3. ARV7 and ARFL in non-cancer CD4 T-cell subpopulation. (A) Bar plot representing gene
expression (mean fold change +/− SD) by qRT-PCR of ARV7 in four CD4 T-cell populations treated
with 5α-dihydrotestosterone (DHT) and enzalutamide (E) individually or combined, by triplicate.
Vehicles (vehic.) of treatments were methanol for DHT and DMSO for E; (B) Bar plot representing gene
expression (mean fold change +/− SD) by qRT-PCR of ARFL in four CD4 T-cell populations treated with
5α-dihydrotestosterone (DHT) and enzalutamide (E) individually or combined, by triplicate. Vehicles
(vehic.) of treatments were methanol for DHT and DMSO for E; T-test, * P < 0.05.
3.3. ARV7, ARFL, KLK3, and PTPRC (CD45) Expression in CTC-Enriched Samples
In order to compare the gene expression from CTC and PBMC, in 12 patients (randomly selected)
blood extraction for PBMC and for CTC-enrichment was simultaneously erformed and tested for the
expression of ARV7, ARFL, KLK3, and the white blood cell arker CD45 (PTPRC). In two patients
(16.7%) no CTC were detected; the remaining 10 (83.3%) had a edian CTC count of 8.5 (range 1–22).
Similar expression of PTPRC was detected i all samples (Figure 4), co firming that the CTC-enriched
sa ples contain contaminating white blood cells. ARV7, ARFL, and KLK3 mRNAs were detected in
all samples in both PBMC a d CTC. Significantly higher levels of ARV7 and KLK3, but not ARFL,
expression were found in CTC samples, compared to PBMC (Figure 4). Although non-significant,
higher levels of the prostate-specific marker KLK3 were in CT -positive samples (≥1 CTC vs. <1 CTC)
and in samples with CTC equal to or more than five (Figure 4).
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3.4. ARV7 and ARFL Expression in PBMC and AA/E Activity 
We collected 55 PBMC samples from 55 AA/E-treated patients, 37 received AA and 18 E. 
Patients’ characteristics are shown in Table 2. 
Table 2. Baseline patients’ characteristics. 
 AA/E cohort Taxane cohort CTC cohort Pre-Post Taxane Cohort 
Number of patients (samples) 55 (55) 81 (92) 22 (24) 28 (56) 
Age (years)     
Median (range) 70.21 (53.3–93.3) 62.85 (32.8–79.4) 70 (41.6–87.1) 62.85 (32.8–79.4) 
Stage at diagnosis, N (%)     
<IV 15 (27.3) 33 (37.7) 5 (20.8) 12 (42.9) 
IV 32 (58.2) 46 (56.8) 15 (62.5) 14 (50) 
No data 8 (14.5) 2 (2.5) 4 (16.7) 2 (7.1) 
Gleason sum at diagnosis, N (%)     
≤7 19 (34.5) 34 (41.9) 8 (33.3) 11 (39.3) 
≥8 30 (54.5) 47 (58) 16 (66.7) 17 (60.7) 
No data 6 (10.9) - - - 
Presence of bone metastases, N (%)     
Yes 51 (92.7) 69 (85.2) 21 (87.5) 25 (89.3) 
No 4 (7.3) 12 (14.8) 3 (12.5) 3 (10.7) 
Presence of visceral metastases, N (%)     
Yes 10 (18.2) 20 (24.7) 7 (29.2) 8 (28.6) 
No 45 (81.8) 61 (75.3) 17 (70.8) 20 (71.4) 
ECOG performance status score, N (%)     
0 14 (25.5) 19 (23.5) 1 (4.2) 4 (14.3) 
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Figure 4. Gene expression comparison between PBMC and CTC-enriched samples. (A) Box plots
representing gene expression (average +/− SD) by qRT-PCR of ARV7, ARFL, KLK3, and PTPRC markers
in PBMC and in circulant tumoral cell (CTC)-enriched samples; (B) Box plots representing gene
expression (average +/− SD) by qRT-PCR of ARV7, ARFL, KLK3, and PTPRC markers in CTC-enriched
samples with <1 CTC vs ≥1 CTC; (C) Box plots re re enting gene xpression (a age +/− SD) by
qRT-PCR of ARV7, ARFL, KLK3, and PTPRC markers in CTC-enriched samples with <5 CTC vs. ≥5
CTC; T-test, * P < 0.05.
3.4. ARV7 and ARFL Expression in PBMC and AA/E Activity
We collected 55 PBMC samples from 55 AA/E-treated patients, 37 received AA and 18 E. Patients’
characteristics are shown in Table 2.
Table 2. Baseline patients’ characteristics.
AA/E Cohort Taxane Cohort CTC Cohort Pre-Post Taxane Cohort
Number of patients (samples) 55 (55) 81 (92) 22 (24) 28 (56)
Age (years)
Median (range) 70.21 (53.3–93.3) 62.85 (32.8–79.4) 70 (41.6–87.1) 62.85 (32.8–79.4)
Stage at diagnosis, N (%)
<IV 15 (27.3) 33 (37.7) 5 (20.8) 12 (42.9)
IV 32 (58.2) 46 (56.8) 15 (62.5) 14 (50)
No data 8 (14.5) 2 (2.5) 4 (16.7) 2 (7.1)
Gleason sum at diagnosis, N (%)
≤7 19 (34.5) 34 (41.9) 8 (33.3) 11 (39.3)
≥8 30 (54.5) 47 (58) 16 (66.7) 17 (60.7)
No data 6 (10.9) - - -
Presence of bone metastases, N (%)
Yes 51 (92.7) 69 (85.2) 21 (87.5) 25 (89.3)
No 4 (7.3) 12 (14.8) 3 (12.5) 3 (10.7)
Presence of visceral metastases, N (%)
Yes 10 (18.2) 20 (24.7) 7 (29.2) 8 (28.6)
No 45 (81.8) 61 (75.3) 17 (70.8) 20 (71.4)
ECOG performance status score, N (%)
0 14 (25.5) 19 (23.5) 1 (4.2) 4 (14.3)
1 or 2 40 (72.7) 62 (76.5) 23 (95.8) 23 (82.1)
No data 1 (1.8) - - 1
Baseline prostate-specific antigen (ng/mL)
Median (range) 38.5 (0.29–328 ) 60.2 (1.04 1284) 27 (1.8–479.6) 27.3 (2.8–675.5)
No data (N) - 1 - -
Baseline hemoglobin concentration (g/L)
Median (range) 123 (84–146) 124 (81–151) 122 (84–498) 132 (97–145)
Baseline alkaline phosphatase (U/L)
Median (range) 177 (53–2448) 229.5 (47–4397) 142 (54–873) 175 (50–1143)
No data (N) 4 2 -
Baseline lactate dehydrogenase
Median (range) 412 (62–1921) 396 (163–2954) 356 (125–949) 378 (163–949)
No data (N) 3 11 - -
Chemotherapy treatment, N (%)
Post 19 (34.5) - - -
Pre 36 (65.5) - - -
Use of AA/E, N (%)
No -
Pre-chemotherapy - 22 (27.2%) 17 (70.8) 16 (57.1)
Never or Post-chemotherapy - 59 (72.8%) 7 (29.2) 12 (42.9)
N: number of cases; ECOG: Eastern Cooperative Oncology Group; AA/E: abiraterone/enzalutamide.
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Median follow-up time was 14.9 months (1.5–57.9). Four (7.3%) patients primarily progressed to
AA/E treatment and 29 (52.7%) responded by PSA. Median PSA-PFS and RX-PFS were 3.6 (3.2–4.1)
and 6.1 (4.1–8.2) months, respectively. Median OS was 16.8 months (12.2–21.5).
Samples were categorized according a selected cut-off in gene expression values, and no differences
in PSA response rate were observed between patients with high or low ARV7 (55% vs. 50%, P = ns)
and ARFL expression (45.5 vs. 55.8 P = ns). However, high ARV7 levels were associated with a shorter
PSA-PFS (hazard ratio (HR) 2.4; 95% confidence interval (CI) 1.1–5.2; P = 0.034) (Figure 5) and high
ARV7/ARFL ratio was an independent prognostic factor for adverse PSA-PFS (HR 8.5; 95% CI 1.8–39.6;
P = 0.006) (Table 3).
Table 3. Univariate and multivariate Cox model for PSA-PFS in AA/E treated patients adjusted for
clinically significant variables (P < 0.1) in univariate analysis.
Univariate Multivariate
PSA-PFS HR 95% CI P-Value HR 95% CI P-Value
ARV7 * 2.357 (1.068–5.2) 0.034 0.326 (0.08–1.325) 0.117
ARFL * 1.718 (0.841–3.511) 0.138 - - -
ARV7/ARFL * 3.8 (1.54–9.39) 0.004 8.492 (1.82–39.6) 0.006
ECOG * 1.953 (0.976–3.908) 0.059 1.990 (0.89–4.41) 0.090
Stage * 1.443 (0.782–2.664) 0.241 - - -
GLEASON * 1.228 (0.662–2.276) 0.515 - - -
Visceral metastases * 1.135 (0.524–2.458) 0.748 - - -
PSA ** 1.00 (1–1.001 0.172 - - -
HB ** 0.961 (0.938–0.985) 0.001 0.964 (0.938–0.992) 0.011
LDH ** 1.001 (1–1.002) 0.003 1.000 (0.999–1.002) 0.438
AP ** 1.003 (1.001–1.005) 0.004 1.001 (0.999–1.003) 0.341
* Variables considered dichotomic; ** Variables considered continuous. ECOG: Eastern Cooperative Oncology
Group; PSA: prostate-specific antigen; HB: hemoglobin concentration; LDH: lactate dehydrogenase; AP: alkaline
phosphatase; HR: hazard ratio; CI: confidence interval. Significant P-Values are shown in bold.
3.5. ARV7 and ARFL Expression in PBMC and Taxane Activity
We collected 92 PBMC samples from 81 patients receiving taxanes (71 docetaxel and 10 cabazitaxel,
and 11 were analyzed for both taxane treatments). Patients’ characteristics are shown in Table 2.
Median follow-up time was 13.82 months (1.37–82.27), median PSA-PFS and RX-PFS were 4.73
(3.6–5.8) and 6.43 (5.2–7.6) months, respectively. Median OS was 15.13 months (10.6–19.7). PSA response
rate to taxanes was 44.6%.
High ARV7 levels correlated with a better PSA-PFS (HR 0.45, 95% CI 0.3–0.7, P = 0.002), RX-PFS
(HR 0.56, 95% CI 0.3–0.9, P = 0.02) and OS (HR 0.54, 95% CI 0.3–0.9, P = 0.013) (Figure 6). Moreover,
higher ARFL was associated with better outcomes for PSA-PFS (HR 0.36, 95%CI 0.22–0.61, P < 0.001)
and RX-PFS (HR 0.45, 95%CI 0.26–0.77, P = 0.004), but not for OS (HR 0.65, 95%CI 0.41–1.1, P = 0.08)
(Figure 6).
In the multivariate analysis, ARV7 and ARFL were independent prognostic factors for favorable
PSA-PFS (HR 0.5, 95%CI 0.3–0.9, P = 0.019 and HR 0.4, 95%CI 0.2–0.7, P = 0.001, respectively) (Table 4).
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Table 4. Univariate and multivariate Cox model for PSA-PFS in taxane-treated patients adjusted for
clinically significant variables (P < 0.1) in univariate analysis.
Univariate Multivariate
PSA-PFS HR 95% CI P-Value HR 95% CI P-Value
ARV7 * 0.449 (0.273–0.739) 0.002 0.487 (0.267–0.889) 0.019
ARFL * 0.364 (0.219–0.607) 0.000 0.366 (0.198–0.676) 0.001
ARV7/ARFL * 0.711 (0.435–1.161) 0.173 - - -
ECOG * 1.479 (0.862–2.539) 0.156 - - -
STAGE * 0.803 (0.511–1.263) 0.343 - - -
GLEASON * 1.256 (0.806–1.958) 0.313 - - -
VISCERAL METASTASES * 0.907 (0.545–1.506) 0.705 - - -
PSA ** 1.001 (1–1.002) 0.005 1.001 (1–1.002) 0.04
HB ** 0.983 (0.969–0.997) 0.015 0.994 (0.979–1.01) 0.469
LDH ** 1.001 (1–1.001) 0.008 1 (1–1.001) 0.604
AP ** 1 (1–1.001) 0.07 1.001 (1–1.001) 0.032
* Variables considered dichotomic; ** Variables considered continuous. ECOG: Eastern Cooperative Oncology
Group; PSA: prostate-specific antigen; HB: hemoglobin concentration; LDH: lactate dehydrogenase; AP: alkaline
phosphatase; HR: hazard ratio; CI: confidence interval. Significant P-Values are shown in bold.
We compared baseline ARV7 and ARFL expression in PBMC between both AA/E and taxane
cohorts (Table 5). We observed that the % of ARV7-high expression samples was significantly higher in
the AA/E than in the taxane cohort (74.5% vs. 41%, odds ratio 4.46, P < 0.001). Regarding to ARFL
expression, taxane-cohort presented higher % of ARFL-high samples than AA/E-cohort patients (68.5%
vs. 21.8%, odds ratio 7.78, P < 0.001). Percentages of high ARV7 and ARFL expression according prior
AA/E or taxane therapy in both cohorts are shown in Table 5.
Table 5. Contingency table showing the frequency of samples with ARV7 and ARFL high and low
expression according to treatments. N: number; AA: abiraterone; E: enzalutamide; OR: odds ratio,
Fisher exact test; * P < 0.05.
ARV7 ARFL
Expression Levels Low High Total Low High Total
Taxane cohort * OR: 3.957; P = 0.011 * OR: 3.75, P = 0.007
No AA/E pre-taxanes N(%) 31 (57.4) 32 (84.2) 63 (68.5) 14 (48.3) 49 (77.8) 63 (68.5)
AA/E pre-taxanes N(%) 23 (42.6) 6 (15.8) 29 (31.5) 15 (51.7) 14 (22.2) 29 (31.5)
Total 54 (58.7) 38 (41.3) 92 (100) 29 (31.5) 63 (68.5) 92 (100)
AA/E cohort OR: 0.414, P = 0.199 * OR: 0.126, P = 0.040
No taxanes pre-AA/E N(%) 7 (50) 12 (29.3) 19 (34.5) 18 (41.9) 1 (8.3) 19 (34.5)
Taxanes pre-AA/E N(%) 7 (50) 29 (70.7) 36 (65.5) 25 (58.1) 11 (91.7) 36 (65.5)
Total 14 (24.4) 41 (74.5) 55 (100) 43 (78.2) 12 (21.8) 55 (100)
3.6. Variations in ARV7 and ARFL Expression Levels in PBMC after Taxanes
We collected 56 paired PBMC samples (pre and post taxane treatment) from 28 patients. Patients’
characteristics are shown in Table 2. We classified samples according their changes in ARV7 and
ARFL expression levels at post respect to pre-treatment status. Those patients whose ARV7 mRNA
levels increased higher than 1 arbitrary unit had longer PSA-PFS (5.9 vs. 3.2 months; P = 0.005) and
OS (38.7 vs. 13.8 months; P = 0.003) than those whose levels decreased more than 1 unit (Figure 7).
No significant results were obtained regarding to changes in ARFL expression in PBMC (data not
shown).
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of ARV7 and ARFL, respectively, according to the Maxstat cut-off. No significant differences were 
observed in taxane response rates between patients with high ARV7 (0% vs. 16.7%) and ARFL (33.3% 
vs. 33.3%) levels, probably because of the small size of the cohort. However, it is of note that none of 
the patients with high ARV7 expression presented PSA response. Regarding survival analysis, high 
ARV7 expression correlated with worse RX-PFS (P = 0.002) and high ARFL correlated with worse OS 
(P = 0.012) (Figure 8). 
Figure 7. Variations in ARV7 and ARFL expression levels after taxanes. Survival analysis in
taxane-treated patients according to changes in ARFL and ARV7 levels in PBMC samples post-taxane
treatment regarding to pre-treatment. (A) Kaplan-Meier curves for PSA progression-free survival
(PSA-PFS); (B) Kaplan-Meier curves for overall survival (OS); HR: hazard ratio; CI: confidence interval.
3.7. ARV7 and ARFL Expression in CTC and Benefit to Taxanes
We also collected 24 CTC-enriched samples from 22 patients prior to receiving taxanes (16 docetaxel,
8 cabazitaxel, and two were analyzed for both taxanes treatments). Patients’ characteristics are shown
in Table 1.
Among the 24 samples, we detected ARV7 and ARFL expression in nine (37.5%) and 13 (54.2%)
samples, respectively. Six of the nine (66.7%) and 10 of the 13 (76.9%) samples expressed high levels
of ARV7 and ARFL, respectively, according to the Maxstat cut-off. No significant differences were
observed in taxane response rates between patients with high ARV7 (0% vs. 16.7%) and ARFL (33.3%
vs. 33.3%) levels, probably because of the small size of the cohort. However, it is of note that none
of the patients with high ARV7 expression presented PSA response. Regarding survival analysis,
high ARV7 expression correlated with worse RX-PFS (P = 0.002) and high ARFL correlated with worse
OS (P = 0.012) (Figure 8).
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performed in vitro experiments using LNCaP cells harboring doxycycline-inducible ARV7 expression 
(LNCaP-ARV7) and 22RV1 docetaxel-resistant cells. After confirming the induction of ARV7 
expression by doxycycline treatment in LNCaP cells (Figure 9), we observed that LNCaP-ARV7 cells 
were more resistant to taxanes than control cells with IC50 around 2.5- and 4.5-fold for docetaxel and 
cabazitaxel, respectively (Figure 9). 22RV1DR cells presented higher levels of ARV7 and ARFL 
expression than parental cells, and were also more resistant to taxanes with IC50 around 16- and 3-
fold for docetaxel and cabazitaxel, respectively (Figure 9). Parental 22RV1 cells treated with androgen 
deprivation therapy (enzalutamide) increased the expression of ARV7 that was reverted by the 
addition of docetaxel (Figure 9). All together these data support the conclusion that ARV7 in tumor 
is modulated by systemic treatment and may be associated with taxane resistance. 
Figure 8. ARFL and ARV7 in CTC from taxane-treated patients. Survival analysis in taxane-treated
patients according to FL and ARV7 levels i CTC sam les pre-treatment. (A) Kaplan-Meier curv s
according to ARV7 levels for radiologic progression-free survival (RX-PFS); B) l i
i t le els for overa l survival (OS); (C) Kaplan-Meier curves according to ARFL level
for RX-PFS; (D) Kaplan-Meier curves according to ARFL levels for OS. HR: hazard ratio; CI: confidence
interval; NA: not achieved.
3.8. ARV7 and Taxane Activity In Vitro
In order to explore the role of ARV7 specifically from tumor cells in taxane response,
we performed in vitro experiments using LNCaP cells harboring doxycycline-inducible ARV7
expression (LNCaP-ARV7) and 22RV1 docetaxel-resistant cells. After confirming the induction
of ARV7 expression by doxycycline treatment in LNCaP cells (Figure 9), we observed that LNCaP-ARV7
cells were more resistant to taxanes than control cells with IC50 around 2.5- and 4.5-fold for docetaxel
and cabazitaxel, respectively (Figure 9). 22RV1DR cells presented higher levels of ARV7 and ARFL
expression than parental cells, and were also more resistant to taxanes with IC50 around 16- and 3-fold
for docetaxel and cabazitaxel, respectively (Figure 9). Parental 22RV1 cells treated with androgen
deprivation therapy (enzalutamide) increased the expression of ARV7 that was reverted by the addition
of docetaxel (Figure 9). All together these data support the conclusion that ARV7 in tumor is modulated
by systemic treatment and may be associated with taxane resistance.
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expression in LNCaP-ARV7 cells induced with different concentrations of doxycycline (ng/mL).
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qRT-PCR. (D) Viability curves in 2 RV1DR vs. 22RV1 cells with both docetaxel and cabazitaxel drugs
after 72 h exposure. IC50 doses are showed. (E) Bar pl ts repr senting ARV7 and ARFL mRNA levels
in 22RV1 cells treated wit enzalutamide (Ez) 60 uM and docetaxel (Dx) 2 nM, separately and in
combination. CT: control. T-test, * P < .05.
4. Discussion
In this paper we report that ARV7 mRNA is not specific to prostate cancer but can also be found
in other types of cells that normally express ARFL, such as monocytes or lymphocytes. We found that
ARV7 expression in PBMC predicted lower AA/E benefit but a better outcome to taxanes. Moreover,
we observed a different role for the expression of ARV7 when it was detected in PBMC or in CTC with
respect to prediction of taxane outcomes suggesting that AR signaling in blood cells may influence
systemic treatment response in patients with mCRPC.
It is well known that in addition to prostate tissue, ARFL receptor is detected in other cells in
the body [26]. Such cells are also susceptible to having the ARV7 splicing form. In this study we
used a very sensitive technique combining cDNA pre-amplification with real-time PCR that allowed
us to detect ARFL expression in different PBMC subpopulations from non-cancer controls and in all
patients’ samples. To a lesser extent, we also detected ARV7 mRNA in most of PBMC subpopulations
from controls and in samples from patients, confirming that the expression of ARV7 is not specific to
prostate cancer. This result agrees with the detection of ARV7 in PBMC of almost all samples analyzed
by Qu et al. [9] and with the finding by Nimir et al. of ARV7 exosomal mRNA in one of five (20%)
healthy volunteers, by using a droplet digital PCR-based approach [27]. We assume that the sensitivity
between different works varies since we and Qu et al. could detect ARFL expression in all the samples
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while Nimir et al. could detect it in only three of five healthy subjects [27]. ARV7 expression in whole
blood from non-cancer individuals was also described by Todenhöfer et al. [8] and Takeuchi et al. [28].
The non-specific detection of ARV7 in blood cells and its potential contamination of CTC-enriched
samples (as observed in our comparative series) could explain, in part, some of the discordant published
results according the predictive value of ARV7 to AA/E or taxane response [7,9,10,13,29–32].
Regarding taxanes, our results in a small cohort of CTC samples showed that patients with
high ARV7 expression presented lower RX-PFS to taxanes, which is consistent with the results of
the TAXYNERGY trial [13]. Accordingly, in vitro experiments showed that ARV7-transfected LNCaP
cells are more resistant to taxanes than parental cells, and that the taxane-resistant cell line 22RV1DR
presented higher levels of ARV7 and ARFL expression than parental cells. Moreover, parental 22RV1
cells treated with androgen deprivation therapy (enzalutamide) increased the expression of ARV7,
which was reverted by the addition of docetaxel. Recently, Cato et al. showed that ARV7 binds ARFL
and represses the transcription of tumor suppressor genes in ARV7-dependent CRPC models [33].
This supports the observed adverse clinical outcome of patients with high ARV7 expression in CTC
treated with both AA/E and taxanes and suggests that ARV7 expression in tumor cells may be an
adverse prognostic factor rather than a predictive factor that may help to discriminate patients for
AA/E or taxane therapies.
ARFL and ARV7 expression in prostatic tumor cells is modulated by systemic treatment. It has
been reported that androgen deprivation therapy increases the expression of ARFL in tumors as well
as the transcription of ARV7, which is closely related to ARFL expression [34]. Because anti-hormonal
treatment in prostate cancer is a systemic therapy, one cannot disregard that this regulation has also an
effect in AR-expressing cells other than prostate cancer cells. We showed in vitro that enzalutamide
significantly increased the expression of ARFL in one (25%) of the 4 CD4 T-cells from controls while
non-significant changes were observed in ARV7 and ARFL expression with DHT or enzalutamide
treatment. Although our results have to be considered exploratory because of the small number of
subjects studied, they support the potential modulation of ARFL or ARV7 expression in PBMC by
systemic treatment. Whether this modulation has as a role in therapy response and in prostate cancer
evolution has not been explored.
A possible explanation for the better response associated with high ARFL and ARV7 levels in PBMC
could be related to the activation of the immune system lead by an active AR pathway and by taxanes.
AR signaling enhances proinflammatory cytokine production by macrophages [35] which could exert
an anti-tumoral activity. Moreover, AR signaling activation has been also related to an increase of
RACK1 expression, a scaffold of protein kinase C (PKC) which stabilizes its conformation and promotes
the activation of several pathways such as the lipopolysaccharide-induced monocytes/macrophage
activation [36]. Taxanes have been also reported as stimulators of the anticancer immune response
exerting an activation of macrophage, T-cell, and NK-cell function [37–39]. Conversely, anti-hormonal
treatment may exert a down-regulation of the PKC signaling molecule RACK1 and a decrease in
monocyte activation on human PBMC [36]. According to this data we hypothesize that a synergistic
effect of taxane- and AR signaling-mediated immune activation could exist in those patients with higher
levels of ARV7 in PBMC. Furthermore, the different immunomodulation exerted by anti-hormonal or
chemotherapy treatment could also explain the different prognostic role of ARV7 detected in blood cells.
In conclusion, our study suggests that the AR pathway in blood cells may have an impact on
the clinical outcome of patients with mCRPC. Testing larger patient populations in further studies
is required to validate these results and deeply understand the mechanisms by which ARFL and its
splicing variant ARV7 from blood or tumor cells are involved in mCRPC evolution.
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